drugset / Trial / NCT07421024
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle
Phase 2
Not yet recruiting
10 enrolled
Morten Hostrup, PhD
Atrogi AB · collabStockholm University · collabUniversity of Copenhagen · collab
NaSingle-groupOpen-labelBasic science
Summary
This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP/PKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.
Timeline
- Start
- 2026-02-20
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATR-258 | Unknown | 0.5 mg | Oral |
| Subject | ATR-258 | Unknown | 2.5 mg | Oral |